News
RVNC
3.290
0.00%
0.000
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Seeking Alpha · 14h ago
Revance Therapeutics: The Takeover Saga Continues As Teoxane Enters The Fray
Seeking Alpha · 17h ago
Crown Laboratories Extension Of Tender Offer To Acquire Revance Therapeutics, Inc. At A Price Of $3.10 Per Share In Cash
Benzinga · 1d ago
Crown Laboratories extends tender offer to acquire Revance Therapeutics
TipRanks · 1d ago
REVANCE THERAPEUTICS INC: TENDER OFFER HAS BEEN EXTENDED UNTIL JANUARY 28
Reuters · 1d ago
Press Release: Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
Dow Jones · 1d ago
*Crown Laboratories Extension Of Tender Offer To Acquire Revance Therapeutics, Inc. RVNC
Dow Jones · 1d ago
Weekly Report: what happened at RVNC last week (0106-0110)?
Weekly Report · 1d ago
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Barchart · 2d ago
Key deals this week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and more
Seeking Alpha · 3d ago
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Barchart · 4d ago
Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Barchart · 4d ago
Revance to Hold Talks With Teoxane on Takeover Proposal
Dow Jones · 6d ago
Revance gains as it plans to enter talks with Teoxane on likely superior bid
Seeking Alpha · 6d ago
Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Barchart · 6d ago
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Barchart · 01/07 19:24
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
Barchart · 01/07 11:09
Hold Rating on Revance Therapeutics Amid Acquisition Bid Uncertainty
TipRanks · 01/07 06:37
Hold Rating Issued Amid Acquisition Uncertainty for Revance Therapeutics
TipRanks · 01/06 18:15
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) – March 04, 2025 Deadline to Join – Contact Levi & Korsinsky LLP
TipRanks · 01/06 17:25
More
Webull provides a variety of real-time RVNC stock news. You can receive the latest news about Revance Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RVNC
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.